A Study of V132 in Healthy Older Participants (V132-001)

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion moved earlier from Jun 21, 2028 to May 5, 2028
  2. Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC
    • Study sites: 9 to 10
    • Secondary endpoints: details revised at 2 of 2 entries
    • Eligibility criteria expanded, about 4 words
  3. Recruitment opened
    • Trial sites expanded: 0 → 9 locations
    • Start date changed from estimate of Aug 17, 2026 to Aug 12, 2026
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
411 trials monitored
See 26 trials at risk
The goal of this study is to learn about the safety and immune response to the V132 vaccine in healthy older adults.
Trial Details
NCT Number NCT07712575
Lead Sponsor Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Healthy
Enrollment 280 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov